The Wall Street Journal
June 24, 2016
By Amy Dockser Marcus

David Adox had ALS and wanted to be an organ donor. But it wasn’t easy to make it happen.

If a neurosurgeon develops a new technique, when can it be considered innovation, and when should it be considered investigation? 

The Boston Globe
By Robert Weisman

Committee member Aaron S. Kesselheim, associate professor at Harvard Medical School, said “the studies provided by [Sarepta] were not adequate and well controlled.” But he acknowledged that it remains an “open question” whether Eteplirsen produces a clinical benefit to patients who take it.

Explore the pros and cons of managing genetic information via public and proprietary companies. 

Even in the US, some controversy persists over the conceptual defensibility of brain death. Around the world, the philosophical defensibility of brain death is even more debatable. 

James Corbett

Harvard Gazette
By John Laidler, Harvard Correspondent
Shifts in the field can allow providers both to prosper and serve patients better, speaker James Corbett says.

Register now for the Annual Bioethics Conference

This multidisciplinary program was co-sponsored by the Center for Bioethics at Harvard Medical School and 

Dr. Mille Solomon

A national conversation about the evidence behind health care and health policy options is an “ethical imperative,” but values conflicts are likely to arise. Dr. Mille Solomon and scholars from the Hastings Center propose a way forward in an article in Health Affairs

Thomas I. Cochrane, M.D.

How one faculty member defines the world of neuroethics

Center faculty members Dr. Spencer Hey and Dr. Aaron Kesselheim examined a lawsuit filed by Amarin Pharmaceutical in May 2015 that sought permission to distribute "truthful and non-misleading" statements relating to an off-label use of its product Vascepa, a pill derived from fish oil. The authors conclude that "informativeness," understood as asserting scientific facts--beyond mere logical truth--"ought to be the standard for regulating commercial speech about pharmaceuticals".